Comparative expression of RAGE and SOX2 in benign and malignant prostatic lesions

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorAboushousha T.
dc.contributor.authorLashen R.
dc.contributor.authorAbdelnaser K.
dc.contributor.authorHelal N.
dc.contributor.authorMoussa M.
dc.contributor.authorOmran Z.
dc.contributor.authorEldahshan S.
dc.contributor.authorEl Ganzoury H.
dc.contributor.otherDepartment of Pathology
dc.contributor.otherUniversity of Modern Sciences and Arts
dc.contributor.otherGiza
dc.contributor.otherEgypt; Faculty of Biotechnology
dc.contributor.otherUniversity of Modern Sciences and Arts
dc.contributor.otherGiza
dc.contributor.otherEgypt; Department of Urorology
dc.contributor.otherTheodor Bilharz Research Institute
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:40:41Z
dc.date.available2020-01-09T20:40:41Z
dc.date.issued2019
dc.descriptionScopus
dc.description.abstractBackground: Prostate cancer (PCa) is a common health problem in elderly. RAGE (Receptor for advanced glycation end products) is overexpressed in multiple human cancers. SOX2 (Sex-determining region Y box 2) also functions as an oncoprotein and promotes cancer progression but the mechanisms involved remain largely unknown. Aim: The current study investigated the expression patterns of RAGE and SOX2 in benign and malignant prostate samples in correlation with the histopathological findings in order to evaluate their role as prognostic markers or therapeutic targets. Methods: Immunohistochemical staining for RAGE and SOX2 antibodies was applied on 87 prostatic biopsies [16 of prostatitis, 20 of benign prostatic hyperplasia (BPH) and 51 of PCa]. Results: Expression of RAGE and SOX2 (percentage of positive cells) was significantly higher in PCa lesions compared with prostatitis (p < 0.01) and BPH (p < 0.0001) and was also significantly higher in prostatitis compared with BPH lesions (p < 0.01). Also, percentage of positive RAGE and SOX2 cells showed a significant stepwise increase from Gleason Grade 3 to Grade 5 and were significantly higher in high Gleason Scores (?8) compared to lower Scores (?7) with statistical significance (p= 0.001). Conclusion: RAGE and SOX2 were up-regulated in prostate cancer lesions, mainly in advanced grades, suggesting an active role of both antigens in the development and progression of prostate cancer and expecting the possibility of their use as therapeutic targets. � 2019, Asian Pacific Organization for Cancer Prevention.en_US
dc.identifier.doihttps://doi.org/10.31557/APJCP.2019.20.2.615
dc.identifier.doiPubMedID30806068
dc.identifier.issn15137368
dc.identifier.otherhttps://doi.org/10.31557/APJCP.2019.20.2.615
dc.identifier.otherPubMedID30806068
dc.identifier.urihttps://t.ly/GrPvB
dc.language.isoEnglishen_US
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.ispartofseriesAsian Pacific Journal of Cancer Prevention
dc.relation.ispartofseries20
dc.subjectCanceren_US
dc.subjectImmunohistochemistryen_US
dc.subjectProstateen_US
dc.subjectRAGEen_US
dc.subjectSOX2en_US
dc.subjectmitogen activated protein kinaseen_US
dc.subjectMOK protein, humanen_US
dc.subjectSOX2 protein, humanen_US
dc.subjecttranscription factor Soxen_US
dc.subjecttumor antigenen_US
dc.subjecttumor markeren_US
dc.subjectageden_US
dc.subjectcancer gradingen_US
dc.subjectcomparative studyen_US
dc.subjectdifferential diagnosisen_US
dc.subjectfollow upen_US
dc.subjecthumanen_US
dc.subjectmaleen_US
dc.subjectmetabolismen_US
dc.subjectprostate hypertrophyen_US
dc.subjectprostate tumoren_US
dc.subjectprostatitisen_US
dc.subjectAgeden_US
dc.subjectAntigens, Neoplasmen_US
dc.subjectBiomarkers, Tumoren_US
dc.subjectDiagnosis, Differentialen_US
dc.subjectFollow-Up Studiesen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMitogen-Activated Protein Kinasesen_US
dc.subjectNeoplasm Gradingen_US
dc.subjectProstatic Hyperplasiaen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectProstatitisen_US
dc.subjectSOXB1 Transcription Factorsen_US
dc.titleComparative expression of RAGE and SOX2 in benign and malignant prostatic lesionsen_US
dc.typeArticleen_US
dcterms.isReferencedByAboushousha, T., Badawy, A., Moussa, M., Evaluation of RAGE (Receptor for Advanced Glycation End-products) expression in gastric carcinoma of Egyptian patients in relation to Helicobacter pylori infection (2016) Annal Pathol Lab Med, 3, pp. 259-268; Aboushousha, T., Mamdouh, S., Hamdy, H., Immunohistochemical and biochemical expression patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-associated Hepatocellular Carcinomas (2018) Asian Pac J Cancer Prev, 19, pp. 219-227; Alexiou, P., Chatzopoulou, M., Pegklidou, K., Demopoulos, V.J., RAGE: a multi-ligand receptor unveiling novel insights in health and disease (2010) Curr Med Chem, 17, pp. 2232-2252; Amornsupak, K., Jamjuntra, P., Warnnissorn, M., High ASMA+ fibroblasts and low cytoplasmic HMGB1+ breast cancer cells predict poor prognosis (2017) Clin Breast Cancer, 17, pp. 441-452; Bae, K-M., Su, Z., Frye, C., Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells (2010) J Urol, 183, pp. 2045-2053; Bae, K-M., Dai, Y., Vieweg, J., Siemann, D.W., Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation (2016) Am J Cancer Res, 5, pp. 1078-1088; Boyle, P., Severi, G., Giles, G.G., The epidemiology of prostate cancer (2003) Urol Clin North Am, 2, pp. 209-217; Briganti, A., Suardi, N., Gallina, A., Predicting the risk of bone metastasis in prostate cancer (2014) Cancer Treat Rev, 40, pp. 3-11; Huang, Y.H., Luo, M.H., Ni, Y.B., Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases (2014) Histopathology, 64; Ibrahim, A.M., Khaled, H.M., Mikhail, N.N., Baraka, H., Kamel, H., Cancer incidence in Egypt: Results of the Nationa population-based cancer registry program (2014) J Cancer Epidemiol, p. 18; Ishiguro, H., Nakaigawa, N., Miyoshi, Y., Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development (2005) Prostate, 64, pp. 92-100; Jia, X., Li, X., Xu, Y., SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell (2011) J Mol Cell Biol, 3, pp. 230-238; Kim, J.Y., Park, H.K., Yoon, J.S., Advanced glycation end product (AGE)-induced proliferation of HEL cells via receptor for AGE-related signal pathways (2008) Int J Oncol, 33, pp. 493-501; Kregel, S., Kiriluk, K.J., Rosen, A.M., Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer (2013) PLoS One, 8; Kuniyasu, H., Chihara, Y., Kondo, H., Ohmori, H., Ukai, R., Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer (2003) Oncol Rep, 10, pp. 1863-1868; Lin, F., Lin, P., Zhao, D., Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis (2012) Cell Prolif, 45, pp. 207-216; Lu, B., Song, X.L., Jia, L.Y., Song, F.L., Zhao, S.C., Differential expressions of the receptor for advanced glycation end products in prostate cancer and normal prostate (2010) Zhonghua Nan Ke Xue, 16, pp. 405-409; Moch, H., Humphrey, P.A., Ulbright, T.M., Reute, V.E., (2016) Tumors of the urinary tract, in 'WHO classification of tumors of the urinary system and male genital organs', pp. 78-133. , 4th Edition, Eds international agency for research on cancer, Lyon; Naz, S., Ahmad, S., Ghafoor, F., Butt, N.S., Akhtar, M.W., Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer (2004) J Coll Physicians Surg Pak, 14, pp. 69-71; Nankali, M., Karimi, J., Goodarzi, M.T., Increased expression of the receptor for advanced glycation end-products (RAGE) is associated with advanced breast cancer stage (2016) Oncol Res Treat, 39, pp. 622-628; Russo, M.V., Esposito, S., Tupone, M.G., SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis (2016) Oncotarget, 15, pp. 12372-12385; Sasahira, T., Akama, Y., Fujii, K., Kuniyasu, H., Expression of receptor for advanced glycation end products and HMGB1/ amphoterin in colorectal adenomas (2005) Virchows Arch, 446, pp. 411-415; Sims, G.P., Rowe, D.C., Rietdijk, S.T., Herbst, R., Coyle, A.J., HMGB1 and RAGE in inflammation and cancer (2010) Annu Rev Immunol, 28, pp. 367-388; Takahashi, K., Tanabe, K., Ohnuki, M., Induction of pluripotent stem cells from adult human fibroblasts by defined factors (2007) Cell, 131, pp. 861-872; Tang, X.B., Shen, X.H., Li, L., Zhang, Y.F., Chen, G.Q., SOX2 overexpression correlates with poor prognosis in laryngeal squamous cell carcinoma (2013) Auris Nasus Larynx, 40, pp. 481-486; Ugolkov, A.V., Eisengart, L.J., Luan, C., Yang, X.J., Expression analysis of putative stem cell markers in human benign and malignant prostate (2011) Prostate, 71, pp. 18-25; Weina, K., Utikal, J., SOX2 and cancer: current research and its implications in the clinic (2014) Clin Transl Med, 3, pp. 19-29; Yan, S., Ramasamy, R., Schmidt, A., Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response (2009) J Mol Med, 87, pp. 235-247; Yang, F., Gao, Y., Geng, J., Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer (2013) Int J Clin Exp Pathol, 6, pp. 2846-2854; Zhang, X., Yu, H., Yang, Y., SOX2 in gastric carcinoma, but not Hath1, is related to patients' clinicopathological features and prognosis (2010) J Gastrointest Surg, 14, pp. 1220-1226
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download
Thumbnail Image
Name:
APJCP_Volume 20_Issue 2_Pages 615-620.pdf
Size:
839.97 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Faculty of Biotechnology Research Paper